A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis
Details
Age
Child
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Principal Investigator
Anna Bruckner, MD
Study ID
Protocol Number: 22-0662
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers